Scroll To Top
Search by Speciality

13th International Congress on Targeted Anticancer Therapies (TAT 2015)

Paris Marriott Rive Gauche Hotel & Conference Center # | Paris, FRANCE
From 300 to 1050 EUR
Event Preview
EXPIRED
This event
is Finished
Title: 13th International Congress on Targeted Anticancer Therapies (TAT 2015)
Specialty: Medical Oncology, Clinical Pharmacology
Dates: From Mar, 2, 2015 to Mar, 4, 2015
Location: Paris, FRANCE
Type: Congress
Registration Cost: From 300 to 1050 EUR
Event Tools
  • Add to Favorites
  • Claim this event
Add to my Calendar
  • Scientific Programm
  • Online registration
  • Exhibition floorplans
  • Sponsorship &
    Exhibition consensus
  • Virtual Booths
Mar
Weather Info (monthly averages) Max Temperature: C / F Min Temperature: C / F The above data in our Weather Info table are temperature predictions for the date of the medical event for Paris, France.
General Info
Event Venue:

Paris Marriott Rive Gauche Hotel & Conference Center #

Paris, FRANCE
Situated in downtown with direct access to major airports and considered one of the premium four-star hotels in Paris, Paris Marriott Rive Gauche Hotel & Conference Center is conveniently located by the Latin Quarter and Saint-Germain-des-Pres. The metro station nearby takes you directly to the Eiffel Tower, Champs Elysees, Montparnasse business district and Notre Dame in less than half an hour. All guest rooms are larger than the average 4-star Paris hotel room. Our four-star Paris hotel features spectacular views, comfortable Revive bedding and upscale shower products. The 70s-inspired R'Yves Great Room concept combines a restaurant, cocktail bar and private lounges as well as a take-away counter for guests to enjoy great food in a trendy atmosphere with wireless Internet. In the central Rive Gauche vicinity of France's capital city, we provide excellent services and facilities for a successful business trip, weekend visit or a holiday away in this unique European destination.  

Business Meetings & Services

  • Our business hotel near Montparnasse offers easy access to the congress center and nearby airports.
  • Experience Paris’ largest business hotel, with 50 event rooms and 4,800 square meters of space.
  • We easily accommodate meeting delegates with our 757 hotel rooms and suites for overnight stays.
  • Ideal for Paris business travel, we can host up to 1,200 delegates in 40 smaller breakout rooms.
  • The culinary team at our business hotel caters for meetings, conferences and exhibitions near Bercy.
  • Click here to download our MeetingMatrix® Certified Diagrams to start planning your next event.  
Visit the Venue to read more
Currency:
EUR
Accreditation:

-

An application for European CME credits from the EACCME / UEMS is under preparation.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

An application for the ESMO label for the TAT 2015 program is pending. If the ESMO label is granted, TAT 2015 will provide ESMO MORA cat1 credits points.

Final announcements of CME credits will be made in early 2015.

Concerned Audience:
  • Medical_Professionals
  • Medical_students
  • Nurses
Event Overview
Welcome message:

TAT congresses are annual meetings on new molecular targets and innovative cancer therapeutics in the early phases of clinical development. Add to these features the high scientific standards, informal atmosphere, and active participation by the world’s leading phase 1 investigators, and you will understand why the TAT Congress series has become the prime international anticancer drug development meeting.


“The home of phase 1 in oncology”


TAT Congresses are more than regular meetings of drug development professionals from academia and pharma and biotech industry. They are the place where the world’s leaders in early-phase development of new cancer therapeutics gather annually, establish and re-new professional and personal relationships, exchange views, discuss matters of common interest, and establish new collaborations.


“I will certainly continue to visit future TAT meetings as I very much enjoy the set-up,

the program, the professional, albeit nearly informal atmosphere, the in-depth scientific

discussions and the friendship among the regular visitors and SAB members”

(Professor Jan Schellens, SAB member TAT Congress, 2002-2014)


Key characteristics


Focus at early-phase development and translational research of new cancer drug targets and agents

Invited lectures by top-level faculty, including phase 1 investigators having hands-on experience with the new agents

Highly international participation from over 30 countries across the globe

Medium-sized meeting offering plenary sessions only

Excellent networking opportunities in a confined setting

Offers accredited learning for medical specialists

“TAT is a meeting that is focusing on early drug development. It has a unique setting,

because you have one single room where everything happens. The size allows for direct

and friendly interactions between key opinion leaders, young investigators and industry”

(Professor Jean-Charles Soria, TAT 2015 President)

Speakers/Faculty:

Mohammed Asmal
Medical Director, Vertex Pharmaceuticals, Boston, MA, USA

Michael B. Atkins
Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center; Professor of Oncology and Medicine (Hematology/Oncology), Georgetown University School of Medicine, Washington, DC, USA

Aditya Bardia
Instructor, Department of Medicine, Harvard Medical School; Assistant Physician, Medical Oncology, Massachusetts General Hospital, Boston, MA, USA

Udai Banerji
Team Leader, Clinical Pharmacology and Trials Team, The Institute of Cancer Research, London, UK

Fiona Blackhall
Medical Oncologist, The Christie; Senior Lecturer, School of Cancer and Enabling Sciences,  The University of Manchester, Manchester, UK

Jan Bogaerts
Senior Statistician, Head of the Statistics Department, EORTC, Brussels, Belgium

Dean Bottino
Oncology Clinical Translational M&S Leader, Millennium: The Takeda Oncology Company, USA

Renier J. Brentjens
Director, Cellular Therapeutics, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Christopher Carpenter
VP-DPU Head, Cancer Epigenetics, Oncology R&D, GlaxoSmithKline, Collegeville, PA, USA

Anthony Chan
Li Shu Fan Medical Foundation Professor of Clinical Oncology, Chief Director, Phase I Clinical Trial Centre, Chairman and Chief of Service, Department of Clinical Oncology, Director, Sir YK Pao Centre for Cancer, Prince of Wales Hospital, Hong Kong, China

Glen Clack
Senior Medical Director, Oncology Translational Medicine Unit, AstraZeneca, Alderley Park, Cheshire, UK

Stephane de Botton
Hematologist, Cancer Institute Gustave Roussy, Villejuif, France

Kapil Dhingra
Managing Member, KAPital Consulting LLC, New York, NY, USA

Gail Eckhardt
Professor and Head of the Division of Medical Oncology, University of Colorado Denver and Health Sciences Center, Aurora, CO, USA

Alexander Eggermont
Director General, Cancer Institute Gustave Roussy, Professor of Oncology, Univerite Paris-Sud, Villejuif/Paris-Sud, France

Lee M. Ellis
Professor of Surgery, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX; Vice Chair Translational Medicine, SWOG, Portland, OR, USA

Charles Ferté
Medical Oncologist, Department of Medical Oncology, Gustave Roussy, Villejuif, France

Justin F. Gainor
Instructor, Department of Medicine, Harvard Medical School; Assistant in Medicine, Massachusetts General Hospital, Boston, MA, USA

Jerome Galon
Research Director (INSERM), Laboratory of Integrative Cancer Immunology, INSERM UMRS1138, Cordeliers Research Center, Paris, France

Matthias Geyer
Research Group Leader,  Center of Advanced European Studies and Research (caesar), Bonn, Germany

Registration Needs updating Register Now
Currency:

EUR

Registration Cost
Type
Early Registration

2015-01-31
Late Registration From: 2015-02-01 To: 2015-02-26
On site Registration
Students, residents in training
300
300
400
industry
850
950
1050
Non-profit
600
700
800
Small biotech
700
700
700

Group Registrations:

Group registrations not allowed

Accompanying Persons:

Accompanying persons not allowed

Registration Documents:
Letter of invitation:
We don’t provide letter of invitation
Letter of confirmation:
We don’t provide Letter of Confirmation
Proof of professional / educational status:
We don’t need Proof of professional/educational status
Online Abstract Submission:

We don’t accept Online Abstracts

Accommodation
Accommodation:

The TAT 2015 organizers have blocked hotel rooms at the congress venue, Marriott Rive Gauche Hotel**** & Conference Center, 17 Boulevard Saint Jacques, Paris, 75014 France.

TAT 2015 delegates may book hotel accommodation here at the special delegate rate of €195,- per night (including taxes), offering the benefit of having the symposium and hotel room under one roof. Marriott Rive Gauche will be the congress headquarters and speakers’ hotel, giving delegates staying here additional opportunities to meet TAT 2015 faculty and colleagues outside congress hours.

All hotel rooms are entirely renovated, are larger than the average 4-star Paris hotel room, and offer spectacular views of the city. The hotel is located in the southern part of downtown Paris. It is easily accessible by public transport from the Paris airports and major railway stations. A metro station is only a 3-minutes walk away.

Scientific Content Up to Date
Submission Info

It is strongly recommended to carefully review the TAT 2015 abstract submission guidelines.

Abstract topics for which abstracts may be submitted:

  • Clinical studies: phase 1
  • Clinical studies: other
  • Drug delivery
  • Drug development methodology & regulatory issues
  • Genomics in drug development
  • Molecular diagnosis and tumor profiling
  • New drugs/targets: cell cycle
  • New drugs/targets: immunological
  • New drugs/targets: cancer metabolism
  • New drugs/targets: DNA repair
  • New drugs/targets: epigenetics & bromodomains
  • New drugs/targets: signaling pathways
  • New drugs/targets: other
  • Preclinical drug profiles
  • Preclinical models
  • Translational research
  • Other topics
Sponsors Exhibitors
General Info

The TAT 2015 Symposium organizers offers excellent sponsoring and exhibition opportunities of interest to a broad range of corporations and organizations. By securing your company’s position in TAT 2015 as a sponsor, grant donor or exhibitor, you will have unprecedented visibility to the world’s oncology community and global leaders in anticancer drug development.

Take a look at the detailed list of:

  • TAT 2015 Secretariat to book your sponsoring/exhibiting arrangement.

    Unrestricted educational grants of EUR 2,500 and above are welcome and will be acknowledged as such.

    available

  • TAT 2015 abstract publication and USB: booked
  • Wireless internet access facilities at the venue: booked
  • NEW! Delegates’ working space with phone/laptop charging facilities: available
  • Conference bags: available
  • NEW! e-Posters (on-site and post-meeting): available
  • Meet-the-professor lunch session: available
  • Lanyards with sponsor logo: booked
  • Poster viewing & welcome reception: booked
  • NEW! Speakers’ lounge: available
  • Advertisement on program book cover: available
  • Advertisement in program book interior: available
  • NEW! Best poster awards: available
  • Coffee breaks: available
  • Insert in delegates’ bags or chair drop: available

Exhibition opportunities and status

  • Standard shell scheme booth: available
  • Exhibition floor space: available
  • Non-profit display space: available

Acknowledgements
Depending on the level of support provided, either for a package of sponsor benefits or a stand-alone benefit, a sponsoring entity will be acknowledged as

  • Diamond sponsor: EUR 30,000 and above
  • Gold sponsor: EUR 20,000 – 30,000
  • Silver sponsor: EUR 10,000 – 20,000
  • Bronze sponsor: EUR 5,000 – 10,000
  • Supporter: EUR 1,000 – 5,000

All sponsors and donors will be acknowledged by means of company logo and/or company name on the congress website, banners at the congress venue and in symposium publications to the extent permitted by applicable laws and regulations. For specific acknowledgements by sponsoring item, see the detailed list of items offered.

interests, contracted separately or as part of a support package, will be considered educational grants and will be used solely to support the expenses of TAT 2015.

Contact
Organising Agency

P.O. Box 77 3480
DB Harmelen
The Netherlands

Kloosterweg 6C
3481 XC Harmelen
The Netherlands

 

Phone: +31 (0)88 089 8101

Fax: +31 (0)88 089 8109

Email: tat@congressbydesign.com

Official Event Webpage
Event map
Revelant Events